Identification and characterization of geometrical isomeric photo degradation product of eprosartan using LC-MS and LC-NMR

Ravi Piyushkumar Shah, Archana Sahu, Saranjit Singh


The degradation of eprosartan was evaluated under ICH/WHO prescribed stress conditions. The drug degraded to only one product under photo alkali condition, whereas it was stable to conditions of hydrolysis, oxidation and thermal stress. The drug and its co-eluting product were well separated on RP-HPLC in a gradient mode. Subsequently, LC-MS/TOF and on-line H/D exchange studies were performed on both of them. The two showed same molecular mass, similar fragment ions and even the same number of labile hydrogens indicating the product to be an isomer of the drug. To confirm the same, 1H and COSY LC-NMR studies were carried out by using an enriched sample. Distinguishing behaviour of chemical shifts proved the product to be (Z)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-enyl)-1H-imidazol-1-yl)methyl)benzoic acid. The structure was further supported by differential LC-MS ion intensities of the drug and the product.2_2_152_157_800


Eprosartan; Degradation behaviour; Photoisomerization; Geometric isomer; LC-MS; LC-NMR

Full Text:

PDF /    /


Cited by

[1]. S. Herrera-Lopez, M. D. Hernando, E. García-Calvo, A. R. Fernández-Alba, M. M. Ulaszewska
Simultaneous screening of targeted and non-targeted contaminants using an LC-QTOF-MS system and automated MS/MS library searching
Journal of Mass Spectrometry  49(9), 878, 2014
DOI: 10.1002/jms.3428

[2]. Rubén M. Maggio, Natalia L. Calvo, Silvana E. Vignaduzzo, Teodoro S. Kaufman
Pharmaceutical impurities and degradation products: Uses and applications of NMR techniques
Journal of Pharmaceutical and Biomedical Analysis  101, 102, 2014
DOI: 10.1016/j.jpba.2014.04.016

[3]. René Holm, David P. Elder
Analytical advances in pharmaceutical impurity profiling
European Journal of Pharmaceutical Sciences  87, 118, 2016
DOI: 10.1016/j.ejps.2015.12.007

[4]. Ravi P. Shah, Archana Sahu, Saranjit Singh
LC-MS/TOF, LC-MSn, on-line H/D exchange and LC-NMR studies on rosuvastatin degradation and in silico determination of toxicity of its degradation products: a comprehensive approach during drug development
Analytical and Bioanalytical Chemistry  405(10), 3215, 2013
DOI: 10.1007/s00216-013-6760-1

[5]. Pradipbhai D. Kalariya, Murali V. N. Kumar Talluri, Vinay D. Gaitonde, Prashant S. Devrukhakar, Ragampeta Srinivas
Quality by design: A systematic and rapid liquid chromatography and mass spectrometry method for eprosartan mesylate and its related impurities using a superficially porous particle column
Journal of Separation Science  37(16), 2160, 2014
DOI: 10.1002/jssc.201301364

[6]. Saranjit Singh, Tarun Handa, Mallikarjun Narayanam, Archana Sahu, Mahendra Junwal, Ravi P. Shah
A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products
Journal of Pharmaceutical and Biomedical Analysis  69, 148, 2012
DOI: 10.1016/j.jpba.2012.03.044


[1]. ICH Topic Q1A (R2), Stability Testing of New Drug Substances and Products, in: International Conference on Harmonisation, IFPMA, Geneva, 2003.

[2]. WHO, Draft Stability Testing of Active Pharmaceutical Ingredients and Pharmaceutical Products, World Health Organization, Geneva, 2007.

[3]. Murakami, T.; Kawasaki, T.; Takemura, A.; Fukutsu, N.; Kishi, N.; Kusu, F. J. Chromatogr. A 2008, 1208, 164-174.

[4]. Shah, R. P.; Kumar, V.; Singh, S. Rapid Commun. Mass Spectrom. 2008, 22, 613-622.

[5]. Novak, P.; Tepes, P.; Ilijas, M.; Fistric, I.; Bratos, I.; Avdagic, A.; Hamersak, Z.; Markovic, V. G.; Dumic, M. J. Pharm. Biomed. Anal. 2009, 50, 68-72.

[6]. Dev, R. V.; Kiran, G. S. U.; Subbaiah, B. V.; Babu, B. S.; Babu, J. M.; Dubey, P. K.; Vyas, K. Magn. Reson. Chem. 2009, 47, 443-448.

[7]. Shah, R. P.; Sahu, A.; Singh, S. J. Pharm. Biomed. Anal. 2010, 51, 1037-1046.

[8]. Shah, R. P.; Singh, S. J. Pharm. Biomed. Anal. 2010, 53, 755-761.

[9]. Hoffman, B. B. in: Brunton, L.L. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th Edition, McGraw-Hill, 859-860, 2006.

[10]. Available at: (accessed on 11 April 2011).

[11]. Hsu, L. C. J. Liq. Chrom. & Rel. Technol. 1998, 21, 1685-1700.

[12]. Xue-Ning, L.; Hong-Rong, X.; Wei-Li, C.; Gang-Yi, L.; Nan-Nan. C.; Chen Y. J. Chromatogr. B 2007, 853, 47-53.

[13]. Ferreirós, N.; Iriarte, G.; Alonsoa, R. M.; Jiménez, R. M.; Ortíz, E. J. Chromatogr. A 2006, 1119, 309-314.

[14]. ICH Topic Q1B, Stability Testing: Photostability Testing of New Drug Substances and Products, in: International Conference on Harmonisation, IFPMA, Geneva, 1996.

[15]. Bakshi, M.; Singh, S. J. Pharm. Biomed. Anal. 2002, 28, 1011-1040.

[16]. Mayer-Helm, B.; Hofbauer, L.; Pani, J. J. Mass. Spectrom. 2010, (Article in Press; doi:10.1002/jms.1757).

[17]. Ge, G. B.; Zhang, R.; Ail, C. Z.; He Y. Q.; Zhang Y. Y.; Liu X. B.; Yang L.; Wang Z. T.; Yang L. Rapid Commun. Mass Spectrom. 2009, 23, 425-432.

[18]. Brum, J.; Hannah, R. Rapid Commun. Mass Spectrom. 1997, 11, 1430-1434.

[19]. Thoma, K.; Kuebler, N.; Reimann, E. Pharmazie 1997, 52, 362-373.

[20]. Albini, A.; Fasani, E. in: Tønnesen H. H. The Photostability of Drugs and Drug Formulations, 2nd Edition, Taylor and Francis, 69-71, 2004.



  • There are currently no refbacks.